Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 20/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4562272 | 0.89 | GRM2 (0.48) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL4562080 | 0.86 | GRM2 (0.48) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL16557118 | 0.84 | GRM2 (0.43) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL17832166 | 0.80 | NOTUM (0.44) | GRM2CYP2C19 | |
| SCHEMBL4561727 | 0.79 | GRM2 (0.31) | GRM2 | |
| SCHEMBL4562407 | 0.76 | GRM2 (0.50) | GRM2 | |
| SCHEMBL4561685 | 0.73 | GRM2 (0.48) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL17904255 | 0.71 | GRM2 (0.43) | GRM2CYP2C9CYP2C19SLC6A3SIGMAR1 | |
| SCHEMBL740989 | 0.68 | GRM2 (0.50) | GRM2CYP2C19 | |
| SCHEMBL16557110 | 0.68 | GRM2 (0.47) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590131-B2 | 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mGluR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-17 | — | — | US | disclosed |
| EP-3230286-B1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-20 | — | — | EP | disclosed |
| US-20190047999-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (JP) | 2019-02-14 | — | — | US | disclosed |
| US-20170362222-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN-CILAG SA (ES) | 2017-12-21 | — | — | US | disclosed |
| US-20170362222-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN-CILAG SA (ES) | 2017-12-21 | — | — | US | disclosed |
| WO-2016092002-A1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590131-B2 | 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mGluR2 receptors | GRM2, GRM1, GRM3 | GRM2 1/4885CYP2C9 3880/4885CYP2C19 3526/4885 |
| US-20190047999-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | GRM2 1/4885CYP2C9 3880/4885CYP2C19 3526/4885 |
| US-20170362222-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | GRM2 1/4885CYP2C9 3880/4885CYP2C19 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.